Matrix Metalloproteinase Inhibitors of Tgfb-Induced Subcapsular Cataract Formation

A composition according to claim 21, wherein the MMPI is wherein the MMPI is selected from the group consisting of:

• ((2R)-[(4-Biphenylylsulfonyl)amino]-N-hydroxyl-3-phenylpropionamide);
• actinonin (3-[[1-[[2-(hydroxymethyl)-1-pyrrolidinyl]carbamoyl]-octano-hydroxamic acid);
• bromocyclic-adenosine monophosphate;
• N-chlorotaurine;
• BATIMISTAT (BB-94);
• CT1166 (N1 {N-[2-(morpholinosulphonylamino)-ethyl]-3-cyclohexyl-2-(S)-propanamidyl}-N4-hydroxy-2-(R)-[3-(4-methylphenyl)propyl]-succinamide);
• estramustine (estradiol-3-bis(2-chloroethyl)carbamat-e);
• eicosa-pentaenoic acid;
• MARIMASTAT (BB-2516);
• matlystatin-B;
• peptidyl hydroxamic acids;
• N-phosphonalkyl dipeptides;
• protocatechuic aldehyde (3,4-dihydroxybenzaldehyde);
• Ro-31-7467 (2-[(5-bromo-2,3-dihydro-6-hydroxy-1,3-dioxo-1H-benz[de]isoquinol-in-2-yl)methyl](hydroxy)-[phosphinyl]-N-(2-oxo-3-azacyclotridecanyl)-4-met-hylvaleramide);
• tetracyclines;
• 1,10-phenanthroline (o-phenanthroline[4-(N-hydroxyamino)-2R-isobutyl-3S-(thiopen-2-ylthiomethyl)-succinyl]-L-p-henylalanine-N-methylamidecarboxyalkylamino-based compounds;
• chelators (EDTA, cysteine, acetylcysteine, D-penicillamine, and gold salts);
• bis(dioxopiperzaine);
• NEOVASTAT;
• KB-R7785;
• ILOMASTAT;
• RPR-122818;
• SOLIMASTAT;
• BB-1101;
• BB-2983;
• BB-3644;
• BMS-275291;
• D-1927, D-5410;
• CH-5902, CH-138;
• CMT-3;
• DERMOSTAT;
• DAC-MMPI;
• RS-1130830 and RS-113-080;
• GM-1339;
• GI-155704A;
• ONO-4817;
• AG-3433, AG-3088, PRINOMASTAT;
• CP-544439;
• POL-641:
• SC-964;
• SD-2590;
• PNU-142769;
• SU-5402;
• PGE-2946979, PGE-4304887;
• fibrolase-conjugate;
• EF-13;
• S-3304;
• CGS-25015 and CGS-27023A;
• XR-168;
• RO1130830;
• D-9120;
• BB-2827;
• BB-1101 (2S-allyl-N1-hydroxy-3R-isobutyl-N4-(1S-methylcarbamoyl-2-phenylethyl)-su-ccinamide), BB-2983, solimastat (N′-[2,2-Dimethyl-[(S)-[N-(2-pyridyl)carba-moyl]propyl]-N4-hydroxy-2(R)-isobutyl-3(S)-methoxysuccinamide), N4-hydroxy-N1-[2-(methylamino)-2-oxo-1-(phenylmethyl)ethyl]-2-(2-methylpr-opyl)-3-[(2-thienylthio)methyl]-, [2R-[1 (S*),2R*,3S*]]-[CAS]), rebimastat (L-Valinamide, N-((2S)-2-mercapto-1-oxo-4-(3,4,4-trimethyl-2,5-dioxo-1-imidazolidinyl)butyl)-L-leucyl-N,3-dimethyl-[CAS]);
• PS-508;
• CH-715;
• nimesulide (Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-[CAS]-), hexahydro-2-[2(R)-[1(RS)-(hydroxycarbamoyl)-4-phenylbutyl]nonanoyl]-N-(-2,2,6,6-etramethyl-4-piperidinyl)-3(S)-pyridazine carboxamide, Cipemastat (1-Piperidinebutanamide, .beta.-(cyclopentylmethyl)-N-hydroxy-Gamma-oxo-A-lpha-[(3,4,4-trimethyl-2,5-dioxo-1-imidazolidinyl)methyl]-,(AlphaR,.beta.R—)-[CAS]), 5-(4′-biphenyl)-5-[N-(4-nitrophenyl)piperazinyl]barbituric acid, 6-methoxy-1,2,3,4-tetrahydro-norharman-1-carboxylic acid, Ro-31-4724 (L-Alanine, N-[2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-L-le-ucyl-, ethyl ester[CAS]), N-hydroxy-2,2-dimethyl-4-((4-(4-pyridinyloxy)phe-nyl)sulfonyl)-, (3R)-[CAS]), PNU-142769 (2H-Isoindole-2-butanamide, 1,3-dihydro-N-hydroxy-Alpha-[(3S)-3-(2-methylpropyl)-2-oxo-1-(2-phenyleth-yl)-3-pyrrolidinyl]-1,3-dioxo-, (AlphaR)-[CAS]), (S)-1-[2-[[[(4,5-Dihydro-5-thioxo-1,3,4-thiadiazol-2-yl)amino]-carbonyl]amino]-1-oxo-3-(pentafluoro-phenyl)propyl]-4-(2-pyridinyl)piperazine, SC-77964, PNU-171829, N-hydroxy-2(R)-[(4-methoxybenzene-sulfonyl)(4-picolyl)amino]-2-(2-tetrahy-drofuranyl)-acetamide, L-758354 ((1,1′-Biphenyl)-4-hexanoic acid, Alpha-butyl-Gamma-(((2,2-dimethyl-1-((methylamino)carbonyl)propyl)amino)c-arbonyl)-4′-fluoro-, (AlphaS-(AlphaR*,GammaS*(R*)))-[CAS]);
• antibodies;
• and analogues or derivatives thereof.